RxDoctor Payments Data

Christopher Davis, DO

Family Medicine · Layton, UTNPI 1346565561

Payments from drug & device makers

$6,901in general payments, 2019–2025

Across 425 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$624
  • Abbott$404
  • Pfizer$381
  • Amgen$342
  • Johnson & Johnson$316
  • plus $4K from 52 others

What the payments were for

  • Food & beverage$6,77398%
  • Education$1282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)90$1,198
AstraZeneca36$624
Abbott20$404
Pfizer21$381
Amgen21$342
Johnson & Johnson(2 entities)21$316
Boehringer Ingelheim16$308
Astellas Pharma US Inc14$299
GSK17$272
Lilly USA, LLC18$265
Novo Nordisk15$223
Otsuka America Pharmaceutical, Inc.10$175
Amarin Pharma, Inc.11$161
Merck9$159
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$144
Sanofi-aventis U.S. LLC9$137
Upsher-smith Laboratories LLC7$116
Axsome Therapeutics, Inc.6$100
Takeda Pharmaceuticals U.S.A., Inc.7$90
Corcept Therapeutics4$80
Biohaven Pharmaceuticals, Inc.5$79
Optinose US, Inc.5$75
Biohaven Pharmaceutical Holding Company Ltd.4$73
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$71
Nestle Healthcare Nutrition Inc.3$65
Ironshore Pharmaceuticals Inc.2$55
Xeris Pharmaceuticals, Inc.3$55
E.r. Squibb & Sons, L.L.C.3$39
Dynavax Technologies Corporation3$36
Baxter Healthcare2$36
Genentech USA, Inc.2$33
Organon3$30
Averitas Pharma Inc.1$30
Supernus Pharmaceuticals, Inc.1$28
Lundbeck LLC1$26
Shire North American Group Inc2$25
Ultragenyx Pharmaceutical Inc.1$24
Melinta Therapeutics, LLC1$24
Shield Therapeutics Inc1$24
Teva Pharmaceuticals USA, Inc.2$23
Avanir Pharmaceuticals, Inc.1$19
Cranial Technologies, Inc1$19
Neurocrine Biosciences, Inc.1$18
Almatica Pharma LLC1$17
Jazz Pharmaceuticals Inc.1$16
Assertio Therapeutics, Inc.1$15
Qiagen, LLC1$15
Alnylam Pharmaceuticals Inc.1$15
Bayer1$14
Phathom Pharmaceuticals, Inc.1$14
Bausch Health US, LLC1$14
Lucid Diagnostics Inc.1$13
Impel Pharmaceuticals Inc.1$12
Bolton Medical Inc1$12
Arbor Pharmaceuticals, Inc.1$12
Medtronic1$11
Dexcom, Inc.1$11
Neuronetics, Inc.1$9

How this compares

$6,901 in reported general payments places this provider in the 85th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$106,795
Medicare patients
179
Services billed
2,819

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide71$99,980
JardianceEmpagliflozin77$80,683
OzempicSemaglutide86$79,410
XareltoRivaroxaban77$64,814
FarxigaDapagliflozin Propanediol84$51,902
EliquisApixaban49$42,007
Tresiba Flextouch U-200Insulin Degludec19$30,587
JanuviaSitagliptin Phosphate56$24,283
TrulicityDulaglutide16$18,965
MyrbetriqMirabegron24$17,877
VraylarCariprazine Hcl12$17,077
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog23$16,295
Soliqua 100-33Insulin Glargine/Lixisenatide11$15,708
Tresiba Flextouch U-100Insulin Degludec24$15,442
LinzessLinaclotide13$10,795

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$265$118,94587 claims
Boehringer IngelheimJardiance$308$80,68377 claims
Novo NordiskOzempic$223$79,41086 claims
Johnson & JohnsonXarelto$316$64,81477 claims
AstraZenecaFarxiga, Symbicort$624$55,86695 claims
PfizerEliquis$381$42,00749 claims
AbbVieVraylar, Linzess$1,198$27,87125 claims
MerckJanuvia$159$24,28356 claims
Astellas Pharma US IncMyrbetriq$299$17,87724 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$137$15,70811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 928 family medicine providers in Utah.

Other family medicine in Layton

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →